DiaMedica Therapeutics
DMAC
About: DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
Employees: 28
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
260% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 5
18% more capital invested
Capital invested by funds: $28.5M [Q1] → $33.6M (+$5.14M) [Q2]
2.57% more ownership
Funds ownership: 17.53% [Q1] → 20.1% (+2.57%) [Q2]
0% more funds holding
Funds holding: 57 [Q1] → 57 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Matthew Caufield
|
$12
|
Buy
Reiterated
|
15 Aug 2025 |
|
Craig-Hallum
Chase Knickerbocker
|
$11
|
Buy
Maintained
|
18 Jul 2025 |
|
Lake Street
Thomas Flaten
|
$14
|
Buy
Maintained
|
18 Jul 2025 |
Financial journalist opinion
Based on 7 articles about DMAC published over the past 30 days
